Protocol EC-0225-01: A Phase 1 Study of EC0225 Administered Weeks 1 and 2 of a 4-Week Cycle.

Trial Profile

Protocol EC-0225-01: A Phase 1 Study of EC0225 Administered Weeks 1 and 2 of a 4-Week Cycle.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2012

At a glance

  • Drugs EC 0225 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 24 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top